Dapansutrile is an orally active, specific and potent inhibitor of NLRP3 inflammasome activation that decreases IL-1β and IL-18 release. Dapansutrile exhibits no effect on NLRC4 and AIM2 inflammasomes activation. It appears that Dapansutrile directly interact with NLRP3. It does not show hematological, or organ toxicities in humans at oral doses up to 1,000 mg/day
orally active, specific and potent inhibitor of NLRP3 inflammasome activation; anti-inflammatory
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse
Journal of Cardiovascular Pharmacology, 73(4), 215-222 (2019)
NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis
Arthritis Research & Therapy, 20(1), 169-169 (2018)
OLT1177, a ?-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
Proceedings of the National Academy of Sciences of the USA, 115(7), E1530-E1539 (2018)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.